CO2- laser treatment for Genitourinary Syndrome of Menopause

08/11/2022,
Serge Rozenberg

Share Obgyn  

  • Ann-Sophie Page et al (BJOG 2022 Nov 8 DOI: 10.1111/1471-0528.17335) assessed whether CO2- laser treatment is more effective than sham application in relieving the Most Bothersome Symptom (MBS) in women with Genitourinary Syndrome of Menopause (GSM) using a Single center, sham controlled, double-blind, randomised trial. All participants eventually received three consecutive laser and three consecutive sham applications, either first laser followed by sham, or conversely. 

The authors Conclusions were that In women with GSM, the treatment response 12 weeks after laser application was comparable to that of sham applications. There were neither obvious differences for secondary outcomes. No serious adverse events were reported. 

Next meeting

11/03/2023
Cognitive disorders, depression and work ability at the menopause.

Latest news

06/01/2023
Menopausal hormone therapy reduces the risk of fracture regardless of falls risk or baseline FRAX probability-results from the Women's Health Initiative (WHI) hormone therapy trials